https://orcid.org/0000-0003-2533-6785
References
- ChengSS, YangGJ, WangW, LeungCH, MaDL. Correction to: the design and development of covalent protein-protein interaction inhibitors for cancer treatment. J. Hematol. Oncol.13(1), 102 (2020).
- LuH, ZhouQ, HeJ et al.Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct. Target Ther.5(1), 213 (2020).
- MarchandA, Van Hall-BeauvaisAK, CorreiaBE. Computational design of novel protein-protein interactions–an overview on methodological approaches and applications. Curr. Opin. Struct. Biol.74, 102370 (2022).
- NusseR, CleversH. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell169(6), 985–999 (2017).
- DrukerBJ. Translation of the Philadelphia chromosome into therapy for CML. Blood112(13), 4808–4817 (2008).
- AubreyBJ, StrasserA, KellyGL. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb. Perspect. Med.6(5), a026062 (2016).
- HanelW, MollUM. Links between mutant p53 and genomic instability. J. Cell. Biochem.113(2), 433–439 (2012).
- IvanovAA, KhuriFR, FuH. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol. Sci.34(7), 393–400 (2013).
- ZhongL, LiY, XiongL et al.Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct. Target Ther.6(1), 201 (2021).
- LiH, YangY, HongW, HuangM, WuM, ZhaoX. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct. Target Ther.5(1), 1 (2020).
- MansooriB, MohammadiA, DavudianS, ShirjangS, BaradaranB. The different mechanisms of cancer drug resistance: a brief review. Adv. Pharm. Bull.7(3), 339–348 (2017).
- WeinerGJ. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer15(6), 361–370 (2015).
- BernalF, WadeM, GodesM et al.A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell18(5), 411–422 (2010).
- OyedeleAK, AdelusiTI, OgunlanaAT et al.Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction. J. Mol. Model28(6), 142 (2022).
- RoskoskiRJr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update. Pharmacol. Res.175, 106037 (2022).
- KrishnaS, KumarSB, MurthyTPK, MurahariM. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy. Comput. Biol. Med.134, 104455 (2021).
- TaniguchiK, KarinM. NF-κB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol.18(5), 309–324 (2018).
- ChengSS, QuYQ, WuJ et al.Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer. Acta Pharm. Sin. B12(3), 1390–1405 (2022).
- TripathiR, LiuZ, JainA et al.Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling. Nat. Commun.11(1), 5463 (2020).
- ZhangZ, TanY, HuangC, WeiX. Redox signaling in drug-tolerant persister cells as an emerging therapeutic target. EBioMedicine89, 104483 (2023).